Chaired by David Lillicrap
This site is intended for healthcare professionals only
This site is intended for healthcare professionals only
This independent webcast, led by a faculty comprising international key opinion leaders, aims to promote a better understanding of hemostasis and the complexity of balancing the hemostasis system. New and emerging therapeutic options in phase 3 are discussed, together with their mode of action and physiological role in hemostasis. The latest information on these new strategies is provided and the clinical implications considered.
Publishing date: June 2021
After viewing the webcast, you will be able to:
| Title | Faculty |
|---|---|
|
Welcome and introduction |
David Lillicrap |
|
The physiology of hemostasis |
David Lillicrap |
|
Non-factor replacement therapies: new and emerging therapeutic options for hemophilia |
Amy Shapiro |
|
Translating research data into clinical practice outcomes |
Johnny Mahlangu |
|
Faculty discussion and audience questions |
All, facilitated by David Lillicrap |
|
Conclusion |
David Lillicrap |
Dr David Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, Kingston, Canada. He is the recipient of a Senior Canada Research Chair in Molecular Hemostasis. Between 2008-2014 he served as an Associate Editor of Blood and is currently Co-Editor-in-Chief of the Journal of Thrombosis and Hemostasis.
Dr Lillicrap is a past member of the World Federation of Hemophilia’s (WFH) Medical Advisory Board and a past Chair of the WFH’s Research Committee. He is also a past Chairman of the International Society on Thrombosis and Hemostasis’ (ISTH) Scientific and Standardization Committee and is a current member of the Council of ISTH. His research interests are centered on molecular aspects of the hemostatic system, with a particular emphasis on the potential of molecular genetics and molecular biology to address questions relating to pathological hemostasis. The main foci of interest of his research group are the investigation of the immune response to FVIII, the development and evaluation of novel therapies for hemophilia A, and characterization of the biology and pathobiology of von Willebrand factor.
Research support: Bayer, Biomarin, Biorevativ/Sanofi, CSL-Behring and Octapharma.
Professor Mahlangu is a Personal Professor in Hematology and Head of School of Pathology in the Faculty of Health Sciences of the University of the Witwatersrand and the National Health Laboratory Service in Johannesburg, South Africa. He is also Director of the International Hemophilia Training Centre and Consultant Clinical Hematologist at the Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg. His main area of research is novel therapies in bleeding disorders in which he has served as Principal Investigator for over 70 international multicenter studies. He is currently doing several gene therapy studies in hemophilia.
Professor Mahlangu is current President of the College of Pathologists in South Africa, board member of the South African Medical Research Council, Wits Health Consortium and Poliomyelitis Research Foundation. His past leadership roles include Chair of the Medical and Scientific Advisory Council of the National Hemophilia Foundation of South Africa, President of SA Hematology Society for two non-consecutive terms and an elected Executive member of the World Federation of Hemophilia.
Research support: Biomarin, CSL, Freeline Therapeutics, Novo Nordisk, Novartis, Pfizer, Sanofi and Roche.
Consultant fees: CSL Berhing, Catalyst Biosciences, Freeline Therapeutics, Novo Nordisk, Roche, Sanofi, Spark and Takeda.
Amy Shapiro MD, is Medical Director and CEO of the Indiana Hemophilia and Thrombosis Center (IHTC) in Indianapolis and Adjunct Senior Investigator, Clinical Track at the Blood Research Institute in Milwaukee, WI. After receiving her medical training at New York University School of Medicine in New York City, Dr Shapiro completed her pediatric internship, residency, and fellowship in pediatric hematology/oncology at the University of Colorado Health Sciences Center in Denver. Author or co-author of more than 320 journal articles, abstracts and textbook chapters, Dr Shapiro is clinically focused on improving treatment for people with rare bleeding disorders. She has served on the National Hemophilia Foundation’s Medical and Scientific Advisory Council as well as on several boards for the National Institutes of Health in Data Safety Monitoring and Clinical Trial Review. Dr Shapiro currently serves on the FDA Blood Products Advisory Committee. As one of the founders of the American Thrombosis and Hemostasis Network (ATHN), she has served as Co-Chairman of the Board of Directors and remains active on various ATHN committees. Dr Shapiro has been honored with the National Hemophilia Foundation Physician of the Year Award and, most recently, received their Leadership in Research Award. Among other accomplishments, she has also received the Distinguished Hoosier Award in Indiana.
Research support: Research-Agios, Bioverativ. Kedrion, OPKO, Octapharma, BioMarin, Catalyst Biosciences, Genentech/Roche, Prometic, Novo Nordisk, Sangamo, Sigilon and Takeda.
Consultant fees: BioMarin, Catalyst Biosciences, Genentech/Roche, Prometic, Novo Nordisk, Sangamo, Sigilon and Takeda.
Honoraria/research fees: paid to IHTC.
This program is intended for specialists (primarily hematologists) treating patients with hemophilia in Europe, United States, Canada and Japan.
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates this live or on-demand activities for a maximum of 1 AMA PRA Category 1 Credit™.
Expiration date: 20th July 2022
NACCME designates the live and on-demand activities, respectively, a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To claim your credits for participating in the accredited activities, you will need to take part in the full live or on-demand session, then fill out the short evaluation form at the end of the activity and complete the appropriate details.
NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.
NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Greaton Sellers, Catherine Wild, Alba Ruzafa and Marie Le Solliec. The Planning Committee have no financial relationships to disclose.
This program is made possible thanks to an independent educational grant from Novo Nordisk Health Care AG.
